Streetbeat News

Stock Prices

VST

Vistra shares rose following Jefferies' initiation of coverage with a Buy rating and a price target of $99.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:13 pm

W

Wayfair Inc (NYSE:W) shares rose by 8% as the home furnishings sector showed signs of recovery, driven by RH's strong earnings report. RH's results suggest increased consumer demand and easing supply chain pressures, potentially benefiting Wayfair.

Portfolio Pulse from Henry Khederian

September 13, 2024 | 2:13 pm

U

Unity Software's stock price is rising following Stifel's decision to increase its price target from $20 to $25.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:11 pm

LAUR

Laureate Education's stock is rising following the announcement of a $100 million stock repurchase program.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:10 pm

BCAX

The trading halt for an IPO security has been updated, and the security is now released for quotation as of 10:10:00 AM ET.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:10 pm

CCCC

C4 Therapeutics presented promising Phase 1 trial data for CFT1946, a treatment for BRAF V600 mutant solid tumors, at the ESMO Congress 2024. The drug showed good tolerance, no dose-limiting toxicities, and early anti-tumor activity, with further data expected in 2025.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:05 pm

TSM

Deep-pocketed investors are showing significant interest in Taiwan Semiconductor (NYSE:TSM) with a mix of bullish and bearish options activities. The options activity suggests a potential price range of $120 to $250. TSM's stock is currently up 0.96% at $173.08, with RSI indicators hinting at an overbought condition.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 2:04 pm

BNTX

Wealthy investors have taken a bearish stance on BioNTech (NASDAQ:BNTX) through options trading, with 63% of trades being bearish. The options activity suggests a price target range of $95 to $200. Despite a recent 6.46% price increase to $111.78, analysts have mixed ratings, with a consensus target price of $105.67.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 2:04 pm

AGEN

Botensilimab and Balstilimab have shown promising clinical responses in treating refractory sarcomas, as presented at ESMO 2024. The combination demonstrates broad and durable activity in advanced sarcoma patients.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:04 pm

RLGT

Radiant Logistics shares rose following the release of their Q4 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:04 pm